Michael Mollerus
Lawyers
Filters
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Emerson €1 billion and $500 million notes offering
The investment-grade debt consists of three tranches of notes
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Paychex $4.1 billion acquisition of Paycor HCM
We are advising Paychex on the transaction
Aptiv corporate reorganization
We advised Aptiv on the corporate reorganization
Merchants Bancorp $230 million preferred stock offering
The depositary shares represent an interest in 7.625% fixed rate non-cumulative perpetual preferred stock